;PMID: 7574421
;source_file_1415.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:49..127] = [t:49..127]
;2)section:[e:131..168] = [t:131..168]
;3)section:[e:172..233] = [t:172..233]
;4)sentence:[e:237..338] = [t:237..338]
;5)sentence:[e:339..439] = [t:339..439]
;6)sentence:[e:440..611] = [t:440..611]
;7)sentence:[e:612..832] = [t:612..832]
;8)sentence:[e:833..941] = [t:833..941]
;9)sentence:[e:942..1157] = [t:942..1157]
;10)sentence:[e:1158..1321] = [t:1158..1321]
;11)sentence:[e:1322..1533] = [t:1322..1533]
;12)section:[e:1537..1581] = [t:1537..1581]

;section 0 Span:0..44
;Ann Acad Med Singapore  1995 May;24(3):393-8
(SEC
  (FRAG (NNP:[0..3] Ann) (NNP:[4..8] Acad) (IN:[9..12] Med)
        (NNP:[13..22] Singapore) (CD:[24..28] 1995) (NNP:[29..32] May)
        (CD:[32..36] ;24-LRB-) (CD:[36..37] 3) (-RRB-:[37..38] -RRB-)
        (CD:[38..42] :393) (::[42..43] -) (CD:[43..44] 8)))

;sentence 1 Span:49..127
;Association of activated proto-oncogenes ras and myc in colorectal
;carcinomas.
;[90..93]:gene-rna:"ras"
;[98..101]:gene-rna:"myc"
;[105..126]:malignancy:"colorectal carcinomas"
(SENT
  (NP-HLN
    (NP (NN:[49..60] Association))
    (PP (IN:[61..63] of)
      (NP
        (NP (VBN:[64..73] activated) (AFX:[74..79] proto) (HYPH:[79..80] -)
            (NNS:[80..89] oncogenes))
        (NP (NN:[90..93] ras) (CC:[94..97] and) (NN:[98..101] myc))))
    (PP (IN:[102..104] in)
      (NP (JJ:[105..115] colorectal) (NNS:[116..126] carcinomas)))
    (.:[126..127] .)))

;section 2 Span:131..168
;Smith DR, Elnatan J, Myint T, Goh HS.
(SEC
  (FRAG (NNP:[131..136] Smith) (NNP:[137..139] DR) (,:[139..140] ,)
        (NNP:[141..148] Elnatan) (VBD:[149..151] J,) (NNP:[152..157] Myint)
        (NNP:[158..159] T) (,:[159..160] ,) (NNP:[161..164] Goh)
        (NNP:[165..167] HS) (.:[167..168] .)))

;section 3 Span:172..233
;Department of Colorectal Surgery, Singapore General Hospital.
(SEC
  (FRAG (NNP:[172..182] Department) (IN:[183..185] of)
        (NNP:[186..196] Colorectal) (NNP:[197..204] Surgery) (,:[204..205] ,)
        (NNP:[206..215] Singapore) (NNP:[216..223] General)
        (NNP:[224..232] Hospital) (.:[232..233] .)))

;sentence 4 Span:237..338
;We have examined 60 colorectal carcinomas for activation of two
;proto-oncogenes,  c-myc and c-Ki-ras.
;[257..278]:malignancy:"colorectal carcinomas"
;[319..324]:gene-rna:"c-myc"
;[329..337]:gene-rna:"c-Ki-ras"
(SENT
  (S
    (NP-SBJ (PRP:[237..239] We))
    (VP (VBP:[240..244] have)
      (VP (VBN:[245..253] examined)
        (NP (CD:[254..256] 60)
           (JJ:[257..267] colorectal) (NNS:[268..278] carcinomas))
        (PP (IN:[279..282] for)
          (NP
            (NP (NN:[283..293] activation))
            (PP (IN:[294..296] of)
              (NP
                (NP (CD:[297..300] two) (AFX:[301..306] proto)
                    (HYPH:[306..307] -) (NNS:[307..316] oncogenes))
                (,:[316..317] ,)
                (NP
                  (NP (NN:[319..324] c-myc))
                  (CC:[325..328] and)
                  (NP (NN:[329..337] c-Ki-ras)))))))))
    (.:[337..338] .)))

;sentence 5 Span:339..439
;Over-expression of c-myc mRNA as determined by Northern  analysis was found
;in 58% of cases (35/60).
;[358..363]:gene-rna:"c-myc"
(SENT
  (S
    (NP-SBJ-2
      (NP
        (NP (AFX:[339..343] Over) (HYPH:[343..344] -) (NN:[344..354] expression))
        (PP (IN:[355..357] of)
          (NP (NN:[358..363] c-myc) (NN:[364..368] mRNA))))
      (SBAR (IN:[369..371] as)
        (S
          (NP-SBJ-1 (-NONE-:[371..371] *))
          (VP (VBN:[372..382] determined)
            (NP-1 (-NONE-:[382..382] *))
            (PP-MNR (IN:[383..385] by)
              (NP (JJ:[386..394] Northern) (NN:[396..404] analysis)))))))
    (VP (VBD:[405..408] was)
      (VP (VBN:[409..414] found)
        (NP-2 (-NONE-:[414..414] *))
        (PP (IN:[415..417] in)
          (NP
            (NP (CD:[418..420] 58) (NN:[420..421] %))
            (PP (IN:[422..424] of)
              (NP (NNS:[425..430] cases)))
            (PRN (-LRB-:[431..432] -LRB-)
              (NP
                (NP (CD:[432..434] 35))
                (PP (SYM:[434..435] /)
                  (NP (CD:[435..437] 60))))
              (-RRB-:[437..438] -RRB-))))))
    (.:[438..439] .)))

;sentence 6 Span:440..611
;Activation of the c-Ki-ras gene by  point mutations in codons 12 or 13 as
;determined by mismatch specific  oligonucleotide hybridisation was found in
;35% (21/60) of cases.
;[458..466]:gene-rna:"c-Ki-ras"
;[476..491]:variation-type:"point mutations"
;[495..504]:variation-location:"codons 12"
;[495..501]...[508..510]:variation-location:"codons"..."13"
(SENT
  (S
    (NP-SBJ-3
      (NP
        (NP (NN:[440..450] Activation))
        (PP (IN:[451..453] of)
          (NP (DT:[454..457] the) (NN:[458..466] c-Ki-ras) (NN:[467..471] gene)))
        (PP (IN:[472..474] by)
          (NP
            (NP (NN:[476..481] point) (NNS:[482..491] mutations))
            (PP-LOC (IN:[492..494] in)
              (NP
                (NP
                  (NML-2 (NNS:[495..501] codons))
                  (CD:[502..504] 12))
                (CC:[505..507] or)
                (NP
                  (NML-2 (-NONE-:[507..507] *P*))
                  (CD:[508..510] 13)))))))
      (SBAR (IN:[511..513] as)
        (S
          (NP-SBJ-1 (-NONE-:[513..513] *))
          (VP (VBN:[514..524] determined)
            (NP-1 (-NONE-:[524..524] *))
            (PP-MNR (IN:[525..527] by)
              (NP
                (ADJP (NN:[528..536] mismatch) (JJ:[537..545] specific))
                (NN:[547..562] oligonucleotide) (NN:[563..576] hybridisation)))))))
    (VP (VBD:[577..580] was)
      (VP (VBN:[581..586] found)
        (NP-3 (-NONE-:[586..586] *))
        (PP (IN:[587..589] in)
          (NP
            (NP (CD:[590..592] 35) (NN:[592..593] %)
              (PRN (-LRB-:[594..595] -LRB-)
                (NP
                  (NP (CD:[595..597] 21))
                  (PP (SYM:[597..598] /)
                    (NP (CD:[598..600] 60))))
                (-RRB-:[600..601] -RRB-)))
            (PP (IN:[602..604] of)
              (NP (NNS:[605..610] cases)))))))
    (.:[610..611] .)))

;sentence 7 Span:612..832
;There was a  statistically significant association between activation of
;c-Ki-ras and  over-expression of c-myc (P = 0.03), with 76% of tumours with
;an activated  c-Ki-ras proto-oncogene showing over-expression of c-myc.
;[685..693]:gene-rna:"c-Ki-ras"
;[718..723]:gene-generic:"c-myc"
;[748..755]:malignancy:"tumours"
;[775..783]:gene-rna:"c-Ki-ras"
;[826..831]:gene-generic:"c-myc"
(SENT
  (S
    (NP-SBJ (EX:[612..617] There))
    (VP (VBD:[618..621] was)
      (NP-PRD
        (NP (DT:[622..623] a)
          (ADJP (RB:[625..638] statistically) (JJ:[639..650] significant))
          (NN:[651..662] association))
        (PP (IN:[663..670] between)
          (NP
            (NP
              (NP (NN:[671..681] activation))
              (PP (IN:[682..684] of)
                (NP (NN:[685..693] c-Ki-ras))))
            (CC:[694..697] and)
            (NP
              (NP (AFX:[699..703] over) (HYPH:[703..704] -)
                  (NN:[704..714] expression))
              (PP (IN:[715..717] of)
                (NP (NN:[718..723] c-myc))))))
        (PRN (-LRB-:[724..725] -LRB-)
          (S
            (NP-SBJ (NN:[725..726] P))
            (VP (SYM:[727..728] =)
              (NP (CD:[729..733] 0.03))))
          (-RRB-:[733..734] -RRB-))
        (,:[734..735] ,)
        (PP (IN:[736..740] with)
          (S-NOM
            (NP-SBJ
              (NP (CD:[741..743] 76) (NN:[743..744] %))
              (PP (IN:[745..747] of)
                (NP
                  (NP (NNS:[748..755] tumours))
                  (PP (IN:[756..760] with)
                    (NP (DT:[761..763] an) (VBN:[764..773] activated)
                        (NN:[775..783] c-Ki-ras) (AFX:[784..789] proto)
                        (HYPH:[789..790] -) (NN:[790..798] oncogene))))))
            (VP (VBG:[799..806] showing)
              (NP
                (NP (AFX:[807..811] over) (HYPH:[811..812] -)
                    (NN:[812..822] expression))
                (PP (IN:[823..825] of)
                  (NP (NN:[826..831] c-myc)))))))))
    (.:[831..832] .)))

;sentence 8 Span:833..941
;The association was  significant in left-sided colorectal tumours (P = 0.03)
;but not right-sided (P =  0.5).
;[869..898]:malignancy:"left-sided colorectal tumours"
;[880..898]...[918..929]:malignancy:"colorectal tumours"..."right-sided"
(SENT
  (S
    (NP-SBJ (DT:[833..836] The) (NN:[837..848] association))
    (VP (VBD:[849..852] was)
      (UCP
        (ADJP-PRD
          (ADJP (JJ:[854..865] significant))
          (PP (IN:[866..868] in)
            (NP (JJ:[869..879] left-sided) (JJ:[880..890] colorectal)
                (NNS:[891..898] tumours)))
          (PRN (-LRB-:[899..900] -LRB-)
            (S
              (NP-SBJ (NN:[900..901] P))
              (PP (SYM:[902..903] =)
                (NP (CD:[904..908] 0.03))))
            (-RRB-:[908..909] -RRB-)))
        (CC:[910..913] but) (RB:[914..917] not)
        (FRAG
          (NP (JJ:[918..929] right-sided)
            (NML (-NONE-:[929..929] *?*)))
          (PRN (-LRB-:[930..931] -LRB-)
            (S
              (NP-SBJ (NN:[931..932] P))
              (VP (SYM:[933..934] =)
                (NP (CD:[936..939] 0.5))))
            (-RRB-:[939..940] -RRB-)))))
    (.:[940..941] .)))

;sentence 9 Span:942..1157
;However, whereas only 59% of left side tumours showed at least one of the 
;two changes (ras activation only, or myc activation only or both), 93% of
;right  side tumours showed at least one of the changes (P = 0.01).
;[971..988]:malignancy:"left side tumours"
;[1030..1033]:gene-rna:"ras"
;[1054..1057]:gene-rna:"myc"
;[1091..1110]:malignancy:"right  side tumours"
(SENT
  (S
    (ADVP (RB:[942..949] However))
    (,:[949..950] ,)
    (SBAR-ADV (IN:[951..958] whereas)
      (S
        (NP-SBJ
          (ADVP (RB:[959..963] only))
          (NP (CD:[964..966] 59) (NN:[966..967] %))
          (PP (IN:[968..970] of)
            (NP
              (NML (JJ:[971..975] left) (NN:[976..980] side))
              (NNS:[981..988] tumours))))
        (VP (VBD:[989..995] showed)
          (NP
            (NP
              (QP (IN:[996..998] at) (JJS:[999..1004] least))
              (CD:[1005..1008] one))
            (PP (IN:[1009..1011] of)
              (NP (DT:[1012..1015] the) (CD:[1017..1020] two)
                  (NNS:[1021..1028] changes)))
            (PRN (-LRB-:[1029..1030] -LRB-)
              (NP
                (NP
                  (NP (NN:[1030..1033] ras) (NN:[1034..1044] activation))
                  (ADVP (RB:[1045..1049] only)))
                (,:[1049..1050] ,) (CC:[1051..1053] or)
                (NP
                  (NP (NN:[1054..1057] myc) (NN:[1058..1068] activation))
                  (ADVP (RB:[1069..1073] only)))
                (CC:[1074..1076] or)
                (NP (DT:[1077..1081] both)))
              (-RRB-:[1081..1082] -RRB-))))))
    (,:[1082..1083] ,)
    (NP-SBJ
      (NP (CD:[1084..1086] 93) (NN:[1086..1087] %))
      (PP (IN:[1088..1090] of)
        (NP (JJ:[1091..1096] right) (NN:[1098..1102] side)
            (NNS:[1103..1110] tumours))))
    (VP (VBD:[1111..1117] showed)
      (NP
        (NP
          (QP (IN:[1118..1120] at) (JJS:[1121..1126] least))
          (CD:[1127..1130] one))
        (PP (IN:[1131..1133] of)
          (NP (DT:[1134..1137] the) (NNS:[1138..1145] changes))))
      (PRN (-LRB-:[1146..1147] -LRB-)
        (S
          (NP-SBJ (NN:[1147..1148] P))
          (VP (SYM:[1149..1150] =)
            (NP (CD:[1151..1155] 0.01))))
        (-RRB-:[1155..1156] -RRB-)))
    (.:[1156..1157] .)))

;sentence 10 Span:1158..1321
;Twenty-two percent  of left side tumours showed both changes compared with
;35% of right side  tumours, although this result did not achieve significance
;(P = 0.2).
;[1181..1198]:malignancy:"left side tumours"
;[1240..1259]:malignancy:"right side  tumours"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[1158..1168] Twenty-two) (NN:[1169..1176] percent))
      (PP (IN:[1178..1180] of)
        (NP
          (NML (JJ:[1181..1185] left) (NN:[1186..1190] side))
          (NNS:[1191..1198] tumours))))
    (VP (VBD:[1199..1205] showed)
      (NP (DT:[1206..1210] both) (NNS:[1211..1218] changes))
      (S-ADV
        (NP-SBJ-1 (-NONE-:[1218..1218] *))
        (VP (VBN:[1219..1227] compared)
          (NP-1 (-NONE-:[1227..1227] *))
          (PP-CLR (IN:[1228..1232] with)
            (NP
              (NP (CD:[1233..1235] 35) (NN:[1235..1236] %))
              (PP (IN:[1237..1239] of)
                (NP
                  (NML (JJ:[1240..1245] right) (NN:[1246..1250] side))
                  (NNS:[1252..1259] tumours)))))))
      (,:[1259..1260] ,)
      (SBAR-ADV (IN:[1261..1269] although)
        (S
          (NP-SBJ (DT:[1270..1274] this) (NN:[1275..1281] result))
          (VP (VBD:[1282..1285] did) (RB:[1286..1289] not)
            (VP (VB:[1290..1297] achieve)
              (NP (NN:[1298..1310] significance))
              (PRN (-LRB-:[1311..1312] -LRB-)
                (S
                  (NP-SBJ (NN:[1312..1313] P))
                  (VP (SYM:[1314..1315] =)
                    (NP (CD:[1316..1319] 0.2))))
                (-RRB-:[1319..1320] -RRB-)))))))
    (.:[1320..1321] .)))

;sentence 11 Span:1322..1533
;These  results suggest that in left-sided colorectal tumours ras and myc
;cooperate, as  established in vitro, to produce neoplastic transformation
;while different  pathway(s) are involved in right-sided tumours.
;[1353..1382]:malignancy:"left-sided colorectal tumours"
;[1383..1386]:gene-rna:"ras"
;[1391..1394]:gene-rna:"myc"
;[1513..1532]:malignancy:"right-sided tumours"
(SENT
  (S
    (NP-SBJ (DT:[1322..1327] These) (NNS:[1329..1336] results))
    (VP (VBP:[1337..1344] suggest)
      (SBAR (IN:[1345..1349] that)
        (S
          (PP (IN:[1350..1352] in)
            (NP (JJ:[1353..1363] left-sided) (JJ:[1364..1374] colorectal)
                (NNS:[1375..1382] tumours)))
          (NP-SBJ (NN:[1383..1386] ras) (CC:[1387..1390] and)
                  (NN:[1391..1394] myc))
          (VP (VBP:[1395..1404] cooperate) (,:[1404..1405] ,)
            (SBAR-ADV (RB:[1406..1408] as)
              (S
                (NP-SBJ-2 (-NONE-:[1408..1408] *))
                (VP (VBN:[1410..1421] established)
                  (NP-2 (-NONE-:[1421..1421] *))
                  (ADVP (FW:[1422..1424] in) (FW:[1425..1430] vitro)))))
            (,:[1430..1431] ,)
            (S-ADV
              (NP-SBJ (-NONE-:[1431..1431] *))
              (VP (TO:[1432..1434] to)
                (VP (VB:[1435..1442] produce)
                  (NP (JJ:[1443..1453] neoplastic)
                      (NN:[1454..1468] transformation)))))
            (SBAR-ADV (IN:[1469..1474] while)
              (S
                (NP-SBJ-1 (JJ:[1475..1484] different)
                          (NNS:[1486..1496] pathway-LRB-s-RRB-))
                (VP (VBP:[1497..1500] are)
                  (VP (VBN:[1501..1509] involved)
                    (NP-1 (-NONE-:[1509..1509] *))
                    (PP-CLR (IN:[1510..1512] in)
                      (NP (JJ:[1513..1524] right-sided)
                          (NNS:[1525..1532] tumours)))))))))))
    (.:[1532..1533] .)))

;section 12 Span:1537..1581
;PMID: 7574421 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1537..1541] PMID) (::[1541..1542] :) (CD:[1543..1550] 7574421)
        (IN:[1551..1552] -LSB-) (NNP:[1552..1558] PubMed) (HYPH:[1559..1560] -)
        (JJ:[1561..1568] indexed) (IN:[1569..1572] for)
        (NNP:[1573..1581] MEDLINE-RSB-)))
